<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836728</url>
  </required_header>
  <id_info>
    <org_study_id>E20210014</org_study_id>
    <nct_id>NCT04836728</nct_id>
  </id_info>
  <brief_title>Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer</brief_title>
  <acronym>CCICC-002b</acronym>
  <official_title>A Randomized, Multicenter,Open-label Phase II Study is to Evaluate the Effects of Chemotherapy and Sintilimab or in Combination With Autologous Cytokine-induced Killer Cell Immunotherapy in Patients With Stage IV Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective,multicenter, open-labe phase II study is to evaluate the effects of&#xD;
      autologous cytokine-induced killer cell immunotherapy combination with PD-1 inhibitor and&#xD;
      chemotherapy in the first-line treatment of IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Time Frame: 2 years</time_frame>
    <description>ORR was calculated by the percentage of patients with a confirmed complete (CR) or partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Time from the first use of the study drug to the death of the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Time from the first dose of study drug to the first disease progression (imaging)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <condition>First-line Treatment</condition>
  <arm_group>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Albumin paclitaxel intravenous infusion 260mg/m2 d2; Carboplatin intravenous infusion AUC5 d2; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IBI308 intravenous infusion 200mg d1; Pemetrexed intravenous infusion 500mg/m2 d2 or Albumin paclitaxel intravenous infusion 260mg/m2 d2; Carboplatin intravenous infusion AUC5 d2;</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CIK cell injection</intervention_name>
    <description>CIK cells, more than 1x10^10 (10 billion ), intravenous infusion,d14; Q3W.</description>
    <arm_group_label>arm 1</arm_group_label>
    <other_name>Autologous cytokine-induced killer cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab Injection</intervention_name>
    <description>Sintilimab Injection intravenous infusion 200mg d1</description>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_label>arm 2</arm_group_label>
    <other_name>PD-1 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed intravenous infusion 500mg/m2 d2</description>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_label>arm 2</arm_group_label>
    <other_name>Pemetrexed injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin paclitaxel</intervention_name>
    <description>Albumin paclitaxel intravenous infusion 260mg/m2 d2</description>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_label>arm 2</arm_group_label>
    <other_name>Albumin paclitaxel Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin intravenous infusion AUC5 d2</description>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_label>arm 2</arm_group_label>
    <other_name>Carboplatin injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Agreeing to participate in this study and signing a written informed consent. Male or&#xD;
             female,from 18 to 75 years (including 18 and 75 years). The life expectancy will be&#xD;
             longer than 3 months and can be followed up. Patients with stage IV NSCLC were&#xD;
             confirmed by histological /cytological and imaging examinations. According to RECIST&#xD;
             1.1 standard, there will be at least one measurable lesion.&#xD;
&#xD;
        Initial medical treattment.Patients with adenocarcinoma need wild type of EGFR gene and ALK&#xD;
        fusion gene negative to be included in this study.&#xD;
&#xD;
        ECOG score will be 0 or 1 within 7 days before randomization.&#xD;
&#xD;
        Within 14 days before the start of treatment, the results of laboratory test of blood&#xD;
        routine, liver, kidney function and hormone levels must be met the following criteria:&#xD;
&#xD;
        White blood cells: more than 3.0 × 109/L; Platelets: more than 100 × 109/L; Neutrophils:&#xD;
        more than 1.5 × 109/L; Hemoglobin: more than 80g/L; Serum glutamate pyruvate transaminase:&#xD;
        less than 2.5 folds of the upper normal limit (ULN); Serum glutamic-oxal (o) acetic&#xD;
        transaminase: less than 2.5 × ULN; Serum bilirubin: less than 1.25 × ULN; Serum creatinine:&#xD;
        less than 1.25 × ULN. Cortisol and thyroid function will be in the normal range.&#xD;
&#xD;
        The toxicity and side effects of previous chemotherapy will must be alleviated to grade 1&#xD;
        or below (except hair loss).&#xD;
&#xD;
        Female subjects must take effective contraceptive measures throughout the study period;&#xD;
        serum or urine pregnancy test results must be negative during screening and the whole study&#xD;
        period.&#xD;
&#xD;
        Male subjects should take effective contraceptive measures from the beginning of treatment&#xD;
        to within 6 months after the end of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who meet any of the following criteria could not participate in this study:&#xD;
&#xD;
        Adenocarcinoma subjects with EGFR sensitive mutation or ALK translocation; molecular&#xD;
        detection of EGFR-sensitive mutations or ALK translocations is not required in squamous&#xD;
        carcinoma patients.&#xD;
&#xD;
        NSCLC that had received chemotherapy in the past. Other malignant tumors needed treatment&#xD;
        within five years. Allogeneic tissue/organ transplantation. Participating in research drug&#xD;
        therapy within 4 weeks before the first administration of the trial.&#xD;
&#xD;
        Systemic glucocorticoid therapy or any other form of immunosuppressive therapy (except&#xD;
        glucocorticoid preconditioned with docetaxel) is being administered within 3 days before&#xD;
        the first administration of the experimental therapy.&#xD;
&#xD;
        Received anti-tumor monoclonal antibody (mAb), chemotherapy, targeted small molecule&#xD;
        therapy or major surgery within 4 weeks before the first use of the drug; received chest&#xD;
        radiotherapy greater than 30 Gy within 6 months before the first use of the drug; and&#xD;
        received chest radiotherapy with 30 Gy or less within 1 month before the first use of the&#xD;
        drug.&#xD;
&#xD;
        Previous treatment with PD-1/PD-L1 antibodies. Over the past two years, patients with&#xD;
        active autoimmune diseases requiring systemic treatment, such as the use of&#xD;
        corticosteroids, or immunosuppressants. Substitution therapy (such as thyroxine, insulin,&#xD;
        or physiological corticosteroid replacement therapy for adrenal or pituitary dysfunction)&#xD;
        is not a systemic treatment.&#xD;
&#xD;
        Patients with congenital or acquired immunodeficiency (e.g. HIV-infected persons), active&#xD;
        hepatitis B (HBV-DNA &gt; 10^3 copies/ml) or hepatitis C (hepatitis C antibody positive), and&#xD;
        HCV-RNA higher than the detection limit of the analytical method.&#xD;
&#xD;
        Subjects with active central nervous system (CNS) metastases and/or cancerous meningitis.&#xD;
&#xD;
        Patients with active infections requiring systemic intravenous therapy. Mental illness or&#xD;
        other illnesses, such as uncontrollable heart disease or pulmonary disease, diabetes, etc.&#xD;
&#xD;
        Subjects who are known to be allergic to any of the constituents of the drug being studied.&#xD;
&#xD;
        Subjects with a recent history of drug abuse (including alcohol) within one year.&#xD;
&#xD;
        Compliance is poor and can not cooperate with clinical research. Female subjects who are&#xD;
        pregnant or breastfeeding, or who are expected to be pregnant during the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Liu, MD. Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiubao Ren, MD. Ph.D</last_name>
    <phone>86-22-23340123</phone>
    <phone_ext>3173</phone_ext>
    <email>renxiubao@tjmuch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Liu, MD. Ph.D</last_name>
    <phone>86-22-23340123</phone>
    <phone_ext>3172</phone_ext>
    <email>liangcoh@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>This is a multicenter, prospective clinical trial. Eight centers provide data to each other.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>3 years</ipd_time_frame>
    <ipd_access_criteria>All patients</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

